Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
8 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to TuHURA Biosciences, Inc.’s names, not what it holds today.
Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 2 in 2023
Applications published
11
since 2001, to Dec 31, 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Del Mar Pharmaceuticals (BC) Limited a subsidiary
CA, as the owner printed on each patent
8 publishedAdgero Biopharmaceuticals Holdings, Inc. a subsidiary
US, as the owner printed on each patent
2 publishedDel Mar Pharmaceuticals (BC) Ltd. a subsidiary
named as the applicant on its applications, in CA
1 publishedNames not counted (2)
DelMar Pharmaceuticals, Inc.
Most of its patents print CA; this name counts in US. 10 granted and 10 published under it are not counted.
DelMar Pharmaceuticals, Inc.
Most of its patents print CA; this name counts in US. 0 granted and 20 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 8, 2023 | 11,717,505 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Jan 3, 2023 | 11,541,027 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Sep 20, 2022 | 11,446,274 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Feb 1, 2022 | 11,234,955 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Jun 8, 2021 | 11,026,914 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Mar 17, 2020 | 10,591,445 | Methods for analysis and resolution of preparations of dianhydrogalactitol and derivatives or analogs thereof | Measurement | Del Mar Pharmaceuticals (BC) Limited |
| Feb 12, 2019 | 10,201,521 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Dec 4, 2018 | 10,145,824 | Analytical methods for analyzing and determining impurities in dianhydrogalactitol | Measurement | Del Mar Pharmaceuticals (BC) Limited |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 26, 2023 | 2023/0338325 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Jun 1, 2023 | 2023/0167124 | Methods for the Production of Nickel (II) Etioporphyrin-I | Organic fine chemistry | Adgero Biopharmaceuticals Holdings, Inc. |
| Jul 21, 2022 | 2022/0226277 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited · patent 11,717,505 granted from it |
| Jun 23, 2022 | 2022/0193024 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Jun 16, 2022 | 2022/0184034 | METHODS FOR TREATING CUTANEOUS METASTATIC CANCERS | Pharmaceuticals | Adgero Biopharmaceuticals Holdings, Inc. |
| May 12, 2022 | 2022/0142966 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Aug 19, 2021 | 2021/0251944 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| Feb 27, 2020 | 2020/0062839 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH VEGF INHIBITORS TO TREAT CANCER | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Ltd. |
| Feb 27, 2020 | 2020/0061054 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH A P53 MODULATOR OR A PARP INHIBITOR | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited |
| May 16, 2019 | 2019/0142783 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | Pharmaceuticals | Del Mar Pharmaceuticals (BC) Limited · patent 11,234,955 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.